Xeris Pharmaceuticals | XERS - Sales Revenues



Xeris Pharmaceuticals reported $71.54M in Sales Revenues for its fiscal quarter ending in June of 2025.


Sales Change Date
Adcock Ingram Holdings ZAR 4.71B 188.47M Dec/2024
Celltrion KRW 961.51B 119.6B Jun/2025
Cspc Pharmaceutical CNY 7.01B 691.61M Mar/2025
Dianthus Therapeutics USD 193K 1.13M Jun/2025
Divis Laboratories Ltd 24.1B 1.75B Jun/2025
Eli Lilly USD 15.56B 2.83B Jun/2025
Kangmei Pharma CNY 1.27B 32.4M Jun/2025
Knight Therapeutics CAD 92.26M 3.31M Sep/2024
Laboratorios Farma 159.7M 274.71M Jun/2025
Malin Corporation EUR 19.2M 2.6M Dec/2020
Medical Developments International AUD 7.54M 0 Dec/2023
Neuren Pharmaceuticals AUD 194.1M 163.93M Dec/2024
Organigram Holdings CAD 70.79M 28.06M Jun/2025
Pacira USD 181.1M 12.18M Jun/2025
Perrigo USD 1.06B 20M Jun/2025
Pharma Mar EUR 56.39M 17.49M Jun/2025
Qiagen NV USD 533.54M 108.24M Jun/2025
Sartorius EUR 884.3M 1.3M Jun/2025
Sino Biopharmaceutical CNY 17.57B 1.7B Jun/2025
Supernus Pharmaceuticals USD 165.5M 15.7M Jun/2025
Tilray USD 308.01M 43.78M Jun/2025
Zhangzhou Pientzehuang Pharmaceutical 2.24B 902.99M Jun/2025